| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1994;57:1534-1539
© 1994 The Society of Thoracic Surgeons
Departments of Thoracic and Vascular Surgery and Heart-Lung Transplantation and Surgicai Pathology, Hopital Marie-Lannelongue, Paris-Sud University, Plessis Robinson, France
Accepted for publication October 12, 1993.
* Address reprint requests to Dr Macchiarini, Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hopital Marie-Lannelongue (Paris-Sud University), 133, Avenue de la Resistance, 92350 Plessis Robinson, France.
We have attempted to identify a biologic rationale for the local aggressiveness and late treatment failure of rejected non-small cell lung cancer involving the thoracic inlet. Tumor specimens from 28 patients who underwent a new transcervical approach were analyzed for the expression of tumor proliferative activity, suppressor-gene p53, intranimoral and peritumoral blood vessel invasion by tumor cells, the presence and degree of angiogenesis (induction of new capillaries and venules), and other biologic variables. Eighty-nine percent of the neoplasms were moderately or poorly differentiated, 89% expressed either an intermediate or high proliferate activity, 39% showed p53 aberrations, 71% exhibited induction of angiogenesis, and 39% had tumors that were positive for blood vessel invasion. With a median follow-up time of 3.5 years (range, 8 to 145+ months), the overall projected 5-year survival was 29% and the median disease-free interval was 23 months. Results of univariate and multivariate analysis of survival and the disease-free interval identified the degree of angiogenesis (density less than 1 versus more than 1 and number of neovessels less than 6 versus more than 6) as the only independent and significant predictors of the disease-free interval. Patients whose tumor showed a density of angiogenesis of 1 or greater and a number of neovessels of 6 or greater faced a significantly (p = 0.0001) higher relative risk of suffering systemic recurrence of their primary tumor than did their low-risk counterparts. Results demonstrate that angiogenesis significantly correlates with late treatment failure (metastasis), and this is acquired at a critical density and number of vessels.
This article has been cited by other articles:
|
|
 |
|
  M. Reck, R. Kaiser, C. Eschbach, M. Stefanic, J. Love, U. Gatzemeier, P. Stopfer, and J. von Pawel A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer Ann. Onc., June 1, 2011; 22(6): 1374 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Medetoglu, M. Z. Gunluoglu, A. Demir, H. Melek, N. Buyukpinarbasili, N. Fener, and S. I. Dincer Tumor angiogenesis in predicting the survival of patients with stage I lung cancer J. Thorac. Cardiovasc. Surg., November 1, 2010; 140(5): 996 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Horn and A. B. Sandler Angiogenesis in the Treatment of Non-Small Cell Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 206 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sandler Bevacizumab in Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4613s - 4616s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Hanrahan and J. V. Heymach Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4617s - 4622s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Park, K. J. Park, Y. S. Kim, S. S. Sheen, K. S. Lee, H. N. Lee, Y. J. Oh, and S. C. Hwang Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer Chest, July 1, 2007; 132(1): 200 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Herbst, A. Onn, and A. Sandler Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications J. Clin. Oncol., May 10, 2005; 23(14): 3243 - 3256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saha, K. R. Sekhar, C. Cao, J. D. Morrow, H. Choy, and M. L. Freeman The Antiangiogenic Agent SU5416 Down-Regulates Phorbol Ester-Mediated Induction of Cyclooxygenase 2 Expression by Inhibiting Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activity Cancer Res., October 15, 2003; 63(20): 6920 - 6927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst and I. J. Fidler Angiogenesis and Lung Cancer: Potential for Therapy Clin. Cancer Res., December 1, 2000; 6(12): 4604 - 4606. [Full Text]
|
|
|
|
|
|
I. G. Duarte, B. L. Bufkin, M. F. Pennington, A. A. Gal, C. Cohen, A. S. Kosinski, K. A. Mansour, and J. I. Miller Angiogenesis As A Predictor Of Survival After Surgical Resection For Stage I Non-Small-Cell Lung Cancer J. Thorac. Cardiovasc. Surg., March 1, 1998; 115(3): 652 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fontanini, S. Vignati, F. Basolo, G. Bevilacqua, M. Lucchi, A. Mussi, C. A. Angeletti, F. Ciardiello, M. De Laurentiis, and S. De Placido Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study J Natl Cancer Inst, June 18, 1997; 89(12): 881 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kessler, B. Gasser, G. Massard, N. Roeslin, P. Meyer, J.-M. Wihlm, and G. Morand Blood Vessel Invasion Is a Major Prognostic Factor in Resected Non-Small Cell Lung Cancer Ann. Thorac. Surg., November 1, 1996; 62(5): 1489 - 1493. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
